FormDSignal
35

FibroBiologics closes $1.2M raise under Regulation D exemption 6(b)

Company raise · Closed · HOUSTON, TX · Form D filed 2026-10-13

FibroBiologics, Inc., a Delaware-incorporated pharmaceutical company based in Houston, closed a $1.2M offering on October 7, 2026, under exemption 6(b). The raise involved one investor and the offering is now fully subscribed.

Note: Offering closed with only one investor; verify investor accreditation status and exemption 6(b) compliance documentation.

operating_company

Why now — by persona

  • Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock

People on the filing

Pete O'HeeronChief Executive Officer
Richard C. CilentoDirector
Robert HoffmanDirector
Victoria NiklasDirector
Kathleen H. RubinsDirector
Leigh SteinbergDirector
Jason D. DavisChief Financial Officer
Ruben A. GarciaGeneral Counsel
Hamid KhojaChief Scientific Officer

Signed by Ruben A. Garia, General Counsel.

Filing contact

The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.

Other filings by this issuer